https://matjournals.net/pharmacy/index.php/JPDRA <p><strong>JPDRA</strong> provide platform to Researchers, Academicians, Scholars, and Professionals in the Pharmacy domain to promulgate their Research / Review / Case studies in the field of Drugs. The journal with a wide scope in the arena of pharmaceutical sciences covers the topics intended to be of interest to a broad audience of pharmaceutical professionals and ideally placed to serve the needs of their readers. The Scope of this Journal includes ICH/GCP, Regulatory Affairs for Medical Devices &amp; Manufacturing Processes, Import and Export of Drugs, Biopharmaceutical Indian Regulations, Good Manufacturing Processes, Drug Mastery File and Dossier, Drug &amp; Biologics Regulatory Affairs, DMF, Ayurvedic Regulations, Medical Diagnostics.</p> en-US Journal of Pharma and Drug Regulatory Affairs (e-ISSN:2582-3043) https://matjournals.net/pharmacy/index.php/JPDRA/article/view/315 <p><span style="font-style: normal !msorm;"><em>The pharmaceutical sector has undergone a significant shift in mindset, transitioning from traditional, reactive quality testing to the more forward-looking and structured approach known as Analytical Quality by Design (AQbD). Rather than testing quality into a method after development, AQbD embeds quality from the very beginning by applying Quality by Design (QbD) principles to analytical science. It promotes a scientific, risk-based strategy that ensures analytical methods are fit for their intended purpose throughout their lifecycle. The AQbD process starts with clearly defining the goal of the method through the Analytical Target Profile (ATP), which outlines both the objective of the analysis and the expected quality of the reported results. To support this, systematic Quality Risk Management (QRM) tools—such as Ishikawa (fishbone) diagrams and Failure Mode and Effects Analysis (FMEA)—are employed to identify, assess, and prioritize variables that may influence method performance. This structured evaluation allows researchers to concentrate on the most critical parameters that truly affect analytical outcomes. Instead of relying on the traditional one-factor-at-a-time (OFAT) approach, AQbD utilizes Design of Experiments (DoE) to study multiple variables simultaneously. This multivariate approach provides deeper insight into how method parameters interact with one another and how these interactions influence critical method attributes, ultimately leading to more robust and reliable analytical procedures. The culmination of this process is the establishment of a Method Operable Design Region (MODR), a multidimensional space of validated input variables that assures method quality. Operating within the MODR provides enhanced method robustness and significant regulatory flexibility, as adjustments within this pre-approved space are not considered changes requiring further filing. While implementation requires a cultural shift and an initial investment in training and resources, AQbD ultimately delivers more robust, flexible, and well-understood analytical methods essential for modern pharmaceutical development and lifecycle management.</em></span></p> Dr. Pratik M Tailor Ashish Mishra Copyright (c) 2026 Journal of Pharma and Drug Regulatory Affairs (e-ISSN:2582-3043) 2026-02-25 2026-02-25 1 10